Search Results

There are 7835 results for: content related to: Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study

  1. Adalimumab for treating rheumatoid arthritis

    Intervention Review

    The Cochrane Library

    Federico Navarro-Sarabia, Rafael Ariza-Ariza, Blanca Hernandez-Cruz and Isidro Villanueva

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD005113.pub2

  2. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 8, August 2015, Pages: 1576–1581, R. Bissonnette, C. Maari, K. Barber, C.W. Lynde and R. Vender

    Version of Record online : 20 JAN 2015, DOI: 10.1111/jdv.12943

  3. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 11-12, December 2014, Pages: 1324–1332, F. Baert, N. Vande Casteele, S. Tops, M. Noman, G. Van Assche, P. Rutgeerts, A. Gils, S. Vermeire and M. Ferrante

    Version of Record online : 2 OCT 2014, DOI: 10.1111/apt.12968

  4. Short-term response to adalimumab in childhood inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 14, Issue 12, December 2008, Pages: 1683–1687, Joshua D. Noe and Marian Pfefferkorn

    Version of Record online : 10 JUL 2008, DOI: 10.1002/ibd.20534

  5. A pilot study of adalimumab in infliximab-allergic patients

    Inflammatory Bowel Diseases

    Volume 10, Issue 4, July 2004, Pages: 333–338, Adrienne Youdim, Eric A. Vasiliauskas, Stephan R. Targan, Konstantinos A. Papadakis, Andrew Ippoliti, Marla C. Dubinsky, Juan Lechago, Jane Paavola, Jaime Loane, Susie K. Lee, Joanne Gaiennie, Katie Smith, Jason Do and Maria T. Abreu

    Version of Record online : 14 DEC 2006, DOI: 10.1097/00054725-200407000-00002

  6. You have free access to this content
    TNF-alpha inhibitors for ankylosing spondylitis

    Intervention Review

    The Cochrane Library

    Lara J Maxwell, Jane Zochling, Annelies Boonen, Jasvinder A Singh, Mirella MS Veras, Elizabeth Tanjong Ghogomu, Maria Benkhalti Jandu, Peter Tugwell and George A Wells

    Published Online : 18 APR 2015, DOI: 10.1002/14651858.CD005468.pub2

  7. You have free access to this content
    Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

    Arthritis & Rheumatism

    Volume 56, Issue 2, February 2007, Pages: 476–488, Dafna D. Gladman, Philip J. Mease, Christopher T. Ritchlin, Ernest H. S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok and Eric H. Sasso

    Version of Record online : 30 JAN 2007, DOI: 10.1002/art.22379

  8. You have free access to this content
    Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 9, November 2014, Pages: 1044–1055, C. Ma, V. Huang, D. K. Fedorak, K. I. Kroeker, L. A. Dieleman, B. P. Halloran and R. N. Fedorak

    Version of Record online : 3 SEP 2014, DOI: 10.1111/apt.12940

  9. You have free access to this content
    Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis

    British Journal of Clinical Pharmacology

    Volume 79, Issue 2, February 2015, Pages: 286–297, David Ternant, Emilie Ducourau, Piéra Fuzibet, Céline Vignault, Hervé Watier, Thierry Lequerré, Xavier Le Loët, Olivier Vittecoq, Philippe Goupille, Denis Mulleman and Gilles Paintaud

    Version of Record online : 20 JAN 2015, DOI: 10.1111/bcp.12509

  10. You have free access to this content
    Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

    Arthritis & Rheumatism

    Volume 50, Issue 5, May 2004, Pages: 1400–1411, Edward C. Keystone, Arthur F. Kavanaugh, John T. Sharp, Hyman Tannenbaum, Ye Hua, Leah S. Teoh, Steven A. Fischkoff and Elliot K. Chartash

    Version of Record online : 6 MAY 2004, DOI: 10.1002/art.20217

  11. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    Brian W Behm and Stephen J Bickston

    Published Online : 23 JAN 2008, DOI: 10.1002/14651858.CD006893

  12. You have free access to this content
    Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis

    Alimentary Pharmacology & Therapeutics

    Volume 26, Issue 11-12, December 2007, Pages: 1509–1520, G. G. KAPLAN, C. HUR, J. KORZENIK and B. E. SANDS

    Version of Record online : 11 OCT 2007, DOI: 10.1111/j.1365-2036.2007.03548.x

  13. You have free access to this content
    Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

    Arthritis & Rheumatism

    Volume 64, Issue 12, December 2012, Pages: 3850–3855, Charlotte L. Krieckaert, Anna Jamnitski, Michael T. Nurmohamed, Piet J. Kostense, Maarten Boers and Gertjan Wolbink

    Version of Record online : 28 NOV 2012, DOI: 10.1002/art.34680

  14. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

    British Journal of Dermatology

    Volume 163, Issue 4, October 2010, Pages: 838–846, P.P.M. Van Lümig, L.L.A. Lecluse, R.J.B. Driessen, P.I. Spuls, J.B. Boezeman, P.C.M. Van De Kerkhof and E.M.G.J. De Jong

    Version of Record online : 22 JUL 2010, DOI: 10.1111/j.1365-2133.2010.09950.x

  15. You have free access to this content
    Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

    Arthritis & Rheumatism

    Volume 48, Issue 1, January 2003, Pages: 35–45, Michael E. Weinblatt, Edward C. Keystone, Daniel E. Furst, Larry W. Moreland, Michael H. Weisman, Charles A. Birbara, Leah A. Teoh, Steven A. Fischkoff and Elliot K. Chartash

    Version of Record online : 10 JAN 2003, DOI: 10.1002/art.10697

  16. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients

    Inflammatory Bowel Diseases

    Volume 16, Issue 11, November 2010, Pages: 1912–1921, Jason M. Swoger, Edward V. Loftus Jr., William J. Tremaine, William A. Faubion, Darrell S. Pardi, Sunanda V. Kane, Karen A. Hanson, W. Scott Harmsen, Alan R. Zinsmeister and William J. Sandborn

    Version of Record online : 1 APR 2010, DOI: 10.1002/ibd.21272

  17. You have free access to this content
    Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 3, February 2011, Pages: 340–348, C. Taxonera, J. Estellés, I. Fernández-Blanco, O. Merino, I. Marín-Jiménez, M. Barreiro-de Acosta, C. Saro, V. García-Sánchez, E. Gento, G. Bastida, J. P. Gisbert, I. Vera, P. Martinez-Montiel, S. Garcia-Morán, M. C. Sánchez and J. L. Mendoza

    Version of Record online : 7 DEC 2010, DOI: 10.1111/j.1365-2036.2010.04531.x

  18. You have full text access to this OnlineOpen article
    Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

    Arthritis & Rheumatism

    Volume 65, Issue 1, January 2013, Pages: 28–38, Michael E. Weinblatt, Michael Schiff, Robert Valente, Désirée van der Heijde, Gustavo Citera, Cathy Zhao, Michael Maldonado and Roy Fleischmann

    Version of Record online : 27 DEC 2012, DOI: 10.1002/art.37711

  19. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis

    British Journal of Dermatology

    Volume 167, Issue s3, November 2012, Pages: 12–20, J. Leman and A.D. Burden

    Version of Record online : 22 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11209.x

  20. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

    British Journal of Dermatology

    Volume 167, Issue 3, September 2012, Pages: 658–667, C. Leonardi, J.M. Sobell, J.J. Crowley, U. Mrowietz, Y. Bao, P.M. Mulani, Y. Gu and M.M. Okun

    Version of Record online : 20 AUG 2012, DOI: 10.1111/j.1365-2133.2012.11041.x